Acapella: hypogammaglobulinemia and jcv status in ocrelizumab-treated patients, year two data

被引：0
|
作者：
Geils, H. [1 ]
Stribling, I. [1 ]
Katz, J. [1 ]
Lathi, E. [1 ]
Douglas, E. [1 ]
Bouley, A. [1 ]
机构：
[1] Elliot Lewis Ctr MS Care, Wellesley, MA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2020年 / 26卷 / 3_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P0280
引用
收藏
页码：256 / 256
页数：1
相关论文
共 50 条
  • [21] Acapella: real-world experience with ocrelizumab: an observational study evaluating safety in patients with relapsing and progressive ms, year three
    Geils, H.
    Stribling, I.
    Katz, J.
    Lathi, E.
    Douglas, E.
    Bouley, A.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 256 - 256
  • [22] Evidence of extensive cellular immune response after SARS-CoV-2 vaccination in ocrelizumab-treated patients with multiple sclerosis
    Mosche Pompsch
    Neslinur Fisenkci
    Peter A. Horn
    Markus Kraemer
    Monika Lindemann
    Neurological Research and Practice, 3
  • [23] Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients
    Georgieva, Zoya G.
    Doffinger, Rainer
    Kumararatne, Dinakantha
    Coles, Alasdair J.
    McCarthy, Claire
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (07) : 1126 - 1130
  • [24] ACAPELLA: Real-World Experience with Ocrelizumab: An Observational Study Evaluating Safety in Patients with Relapsing and Progressive MS, Late Breaking Data
    Douglas, E.
    O'Shea, I.
    Bouley, A.
    Katz, J.
    Lathi, E.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 967 - 967
  • [25] Vaccine against SARS-CoV2-generated Immunity in Ocrelizumab-treated Patients: Longitudinal Assessments (VIOLA): study design and early results
    Kister, I.
    Piquet, A.
    Patskovsky, Y.
    Voloshyna, I.
    Ferstler, N.
    Curtin, R.
    Yogambigai, V.
    Nyovanie, S.
    Rimler, Z.
    Perdomo, K.
    Borko, T.
    Selva, S.
    Gonzalez, J. Parra
    Bacon, T.
    Ryerson, L. Zhovtis
    Raposo, C.
    Priest, J.
    Winger, R.
    Silverman, G. J.
    Krogsgaard, M.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 795 - 796
  • [26] Improvement in Patient-Reported SymptoMScreen Scores Among Ocrelizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis: 1-Year Results From the CASTING Clinical Trial
    Kister, Ilya
    Cutter, Gary
    Buffels, Regine
    Clinch, Susanne
    Wei, Wei
    Vermersch, Patrick
    NEUROLOGY, 2020, 94 (15)
  • [27] Neurofilament Serum Levels Do Not Correlate with Symptom Burden in Stable, Ocrelizumab-Treated MS Patients Enrolled into SYMptom Burden on Ocrelizumab, a Longitudinal Study (SYMBOLS) (P1-1.Virtual)
    McCluskey, Madaline
    Oh, Cheongeun
    Jungquist, Rose-Marie
    Rimler, Zoe
    Douglas, Elizabeth
    Bouley, Andrew
    Lathi, Ellen
    Katz, Joshua
    Kister, Ilya
    NEUROLOGY, 2022, 98 (18)
  • [28] Longitudinal study of immunity to SARS-CoV2 in ocrelizumab-treated MS patients up to 2 years after COVID-19 vaccination
    Kister, Ilya
    Curtin, Ryan
    Piquet, Amanda L.
    Borko, Tyler
    Pei, Jinglan
    Banbury, Barbara L.
    Bacon, Tamar E.
    Kim, Angie
    Tuen, Michael
    Velmurugu, Yogambigai
    Nyovanie, Samantha
    Selva, Sean
    Samanovic, Marie I.
    Mulligan, Mark J.
    Patskovsky, Yury
    Priest, Jessica
    Cabatingan, Mark
    Winger, Ryan C.
    Krogsgaard, Michelle
    Silverman, Gregg J.
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2024, 11 (07): : 1750 - 1764
  • [29] Reduced humoral immune response after mRNA vaccination correlates with breakthrough SARS-CoV-2 infection in ocrelizumab-treated multiple sclerosis patients
    Novak, Frederik
    Bajwa, Hamza
    Coia, John Eugenio
    Nilsson, Anna Christine
    Nielsen, Christian
    Holm, Dorte
    Ostergaard, Kamilla
    Hvidt, Mathilde
    Byg, Keld-Erik
    Johansen, Isik
    Mittl, Kristen
    Rowles, William
    Zamvil, Scott
    Bove, Riley
    Sabatino, Joseph
    Sejbaek, Tobias
    NEUROLOGY, 2023, 100 (17)
  • [30] Hypogammaglobulinemia and infection rates in ocrelizumab treated multiple sclerosis patients over 3 years: a real-world single center study
    Khatri, B.
    Van Zealand, P.
    Tarima, S.
    Schutten, S.
    Baker, A.
    Sershon, L.
    Fenton, K.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 626 - 626
12345